

Correction

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg¹, Thomas M. Cardillo¹, Serengulam V. Govindan¹, Edmund A. Rossi¹, Robert M. Sharkey¹

¹Immunomedics, Inc., Morris Plains, NJ, USA

*Presented in part as a lecture by DMG, "Challenging the Dogmas: Clinical Efficacy of SN-38-conjugated Antibodies in Solid Tumors," at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapy, Barcelona, Spain, November 20, 2014.

Published: March 10, 2020

Copyright: Goldenberg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to an entry error found in one of the triplicate data for the 48-h time-point of stability in human serum *in vitro*, the half-life for drug release has been corrected to 18.82 h from the stated 23.98 h in Figure 1C. The corrected Figure 1C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.




Figure 1: Structures of irinotecan, SN-38, and CL2A-SN-38. (C) *In vitro* serum stability of IMMU-132 in monkey or human serum.

Original article: Oncotarget. 2015; 6:22496–22512. <https://doi.org/10.18632/oncotarget.4318>